Výsledky vyhledávání - "Thomas A. Warr"

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens

Autor: Thomas A. Warr, Rachel Neuwirth, Robert M. Rifkin, Ian W. Flinn, Yousuf Gaffar, James A. Reeves, Veena Charu, James Essell, Yanyan Zhu, Ruben Niesvizky, Billy Clowney, Nashat Y. Gabrail, Dixie-Lee Esseltine, Liviu Niculescu, Jennifer Elliott

Publikováno v: Journal of Clinical Oncology. 33:3921-3929

Purpose The US community-based, phase IIIB UPFRONT trial was designed to compare three frontline bortezomib-based regimens in transplantation-ineligible patients with myeloma. Patients and Methods Patients (N = 502) were randomly assigned 1:1:1 to 24

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3bf1a602f6a21211b6b9191a7b8d2a8
https://doi.org/10.1200/jco.2014.58.7618

Zobrazit plný text záznamu

A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma

Autor: Nancy L. Knudsen, Shani L. Frayo, Britt E Kammerer, Thomas E. Boyd, George R. Oliveira, Oliver W. Press, Ajay K. Gopal, Andrei R. Shustov, Jennifer E. Roden, Thomas A. Warr, John M. Pagel, Lihua E. Budde, Ted Gooley, Tara L. Chen, Michelle M. Zhang

Publikováno v: British Journal of Haematology. 161:183-191

Summary Given the poor outcomes of relapsed aggressive lymphomas and preclinical data suggesting that ≥2·5 μmol/l concentrations of vorinostat synergize with both etoposide and platinums, we hypothesized that pulse high-dose vorinostat could safe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9aededc57537ae5b8377fe4db21aaa3
https://doi.org/10.1111/bjh.12230

Zobrazit plný text záznamu

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Autor: Ruben Niesvizky, Robert M. Rifkin, Billy Clowney, Rachel Neuwirth, Thomas A. Warr, Ian W. Flinn, Deyanira Corzo, Yousuf Gaffar, James A. Reeves, Veena Charu, Nashat Y. Gabrail, James Essell

Publikováno v: Blood. 118:478-478

Abstract 478 Background: The US community-based, phase 3b randomized, open-label, multicenter UPFRONT trial compares the efficacy and safety of three bortezomib (VELCADE®, Vc)-based regimens, VcD (Vc-dexamethasone), VcTD (Vc-thalidomide-dexamethason

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b9791ac7f8a33679f353242461514910
https://doi.org/10.1182/blood.v118.21.478.478

Zobrazit plný text záznamu

Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Autor: Nashat Y. Gabrail, Ian W. Flinn, Veena Charu, Yousuf Gaffar, Hui Huang, Deyanira Corzo, Rachel Neuwirth, Sanggyu Choi, Thomas A. Warr, Ruben Niesvizky, Robert M. Rifkin, Billy Clowney

Publikováno v: Blood. 118:1864-1864

Abstract 1864 Background: In addition to determining the efficacy and safety of different treatment options for MM, the impact of treatment and associated toxicities on patient-reported QoL should be evaluated. The US community-based phase 3b UPFRONT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c1eb95aa7b61649d645776133d38c931
https://doi.org/10.1182/blood.v118.21.1864.1864

Zobrazit plný text záznamu

Pulse High-Dose Vorinostat Can Be Delivered with Rituximab, Ifosphamide, Carboplatin, and Etoposide In Patients with Relapsed Lymphoma: Final Results of a Phase I Trial

Autor: Lihua E. Budde, Ted Gooley, Andrei R. Shustov, Tara Chen, Thomas A. Warr, Oliver W. Press, Michelle M. Zhang, John M. Pagel, George Oliviera, Thomas E. Boyd, Ajay K. Gopal

Publikováno v: Blood. 116:2790-2790

Abstract 2790 Background: The development of more effective front-line regimens for lymphoma (e.g. R-CHOP, BEACOPP) has resulted in lower response rates to salvage regimens such as Ifosphamide, Carboplatin, Etoposide +/− Rituximab (RICE/ICE) and im

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::110a67e747fc7fb0229541d25a90a9bc
https://doi.org/10.1182/blood.v116.21.2790.2790

Zobrazit plný text záznamu

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients

Autor: Thomas A. Warr, Ian W. Flinn, Billy Clowney, James A. Reeves, Yousuf Gaffar, Veena Charu, James Essell, Ruben Niesvizky, Robert M. Rifkin, Nashat Y. Gabrail, Deyanira Corzo, Rachel Neuwirth

Publikováno v: Blood. 116:619-619

Abstract 619 The UPFRONT study is a US community-based, randomized, open-label, multicenter phase 3b trial comparing the safety and efficacy of three bortezomib (Velcade®, Vc)-based regimens, VcD (Vc-dexamethasone), VcTD (Vc-thalidomide-dexamethason

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3932c591ec5a132108a331aff067aa1a
https://doi.org/10.1182/blood.v116.21.619.619

Zobrazit plný text záznamu

A Phase I Study of Vorinostat (V) in Combination with Rituximab (R), Ifosphamide, Carboplatin, and Etoposide (ICE) for Patients with Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma

Autor: Thomas A. Warr, Michelle M. Zhang, John M. Pagel, Tara L. Chen, Andrei R. Shustov, Ajay K. Gopal, Lihua E. Budde, Ted Gooley, George R. Oliveira

Publikováno v: Blood. 114:3696-3696

Abstract 3696 Poster Board III-632 Platinum based regimens such as ICE with or without Rituximab (RICE) have been widely used to treat relapsed or refractory lymphoid malignancies prior to transplantation. However, a significant portion of patients d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3d015d249862cc1ebda4ad7758675f16
https://doi.org/10.1182/blood.v114.22.3696.3696

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání